share_log

Earnings Call Summary | Oncolytics Biotech(ONCY.US) Q1 2024 Earnings Conference

Earnings Call Summary | Oncolytics Biotech(ONCY.US) Q1 2024 Earnings Conference

業績電話會議摘要 | Oncytics Biotech (ONCY.US) 2024 年第一季度業績發佈會
moomoo AI ·  05/10 11:35  · 電話會議

The following is a summary of the Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript:

以下是Oncolytics Biotech, Inc.(ONCY)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Oncolytics Biotech reported a cash position of $29.6 million at the end of Q1 2024, down from $34.9 million at the end of 2023.

  • The company reported a net loss of $6.9 million for the first quarter of 2024, a slight increase from a net loss of $6.4 million in the first quarter of 2023.

  • Research and development expenses for Q1 2024 amounted to $5.7 million, primarily because of increased manufacturing expenses and preparations for upcoming product fills.

  • Oncolytics Biotech報告稱,截至2024年第一季度末,現金狀況爲2960萬美元,低於2023年底的3,490萬美元。

  • 該公司報告稱,2024年第一季度淨虧損690萬美元,較2023年第一季度的淨虧損640萬美元略有增加。

  • 2024年第一季度的研發費用爲570萬美元,這主要是由於製造費用增加以及爲即將到來的產品灌裝做準備。

Business Progress:

業務進展:

  • Oncolytics focused on advancing its proprietary immunotherapeutic product candidate, pelareorep.

  • Enrollment in the anal cancer cohort of the GOBLET study has been extended, potentially leading to a new registrational indication.

  • The company received regulatory approval to move forward with the pela and modified FOLFIRINOX combination study.

  • Overall survival data from the BRACELET-1 breast cancer study is expected in H2 2024.

  • Oncolytics plans to initiate registration-enabling studies in breast and pancreatic cancer.

  • Oncolytics專注於推進其專有的免疫療法候選產品pelareorep。

  • GOBLET研究的肛門癌隊列的註冊人數已延長,這可能會導致新的註冊適應症。

  • 該公司獲得了監管部門的批准,可以推進Pela和改良的FOLFIRINOX聯合研究。

  • BRACELET-1 乳腺癌研究的總體存活數據預計將在2024年下半年公佈。

  • Oncolytics計劃啓動乳腺癌和胰腺癌的註冊研究。

More details: Oncolytics Biotech IR

更多詳情: 腫瘤生物技術 IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論